Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Omnicell Inc is a health information services business based in the US. Omnicell shares (OMCL) are listed on the NASDAQ and all prices are listed in US Dollars. Omnicell employs 3,370 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $147.60 |
|---|---|
| 52-week range | $116.07 - $187.29 |
| 50-day moving average | $174.53 |
| 200-day moving average | $156.51 |
| Wall St. target price | $196.00 |
| PE ratio | 85.485 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $1.73 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $147.6 from 2022-01-25
| 1 week (2022-01-19) | -2.88% |
|---|---|
| 1 month (2021-12-23) | -15.97% |
| 3 months (2021-10-26) | -13.56% |
| 6 months (2021-07-26) | -2.69% |
| 1 year (2021-01-26) | 16.93% |
|---|---|
| 2 years (2020-01-24) | 75.61% |
| 3 years (2019-01-25) | 123.40% |
| 5 years (2017-01-26) | 314.61% |
Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, Omnicell shares trade at around 85x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $153.9 million.
The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 9.97% |
| Gross profit TTM | $415.9 million |
| Return on assets TTM | 3.54% |
| Return on equity TTM | 7.91% |
| Profit margin | 7.5% |
| Book value | $25.33 |
| Market capitalisation | $6.5 billion |
TTM: trailing 12 months
We're not expecting Omnicell to pay a dividend over the next 12 months.
Over the last 12 months, Omnicell's shares have ranged in value from as little as $116.07 up to $187.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 1.0466. This would suggest that Omnicell's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omnicell, Inc. , together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
